scholarly journals Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial

The Lancet ◽  
2017 ◽  
Vol 390 (10104) ◽  
pp. 1747-1757 ◽  
Author(s):  
Dirk Sibbing ◽  
Dániel Aradi ◽  
Claudius Jacobshagen ◽  
Lisa Gross ◽  
Dietmar Trenk ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Acute Coronary Syndrome ◽  
Multicentre Trial ◽  
Coronary Intervention ◽  
Antiplatelet Treatment ◽  
Open Label ◽  
Coronary Syndrome ◽  
Percutaneous Coronary

Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention

2018 ◽  
Vol 29 (1) ◽  
pp. 53-59 ◽  
Author(s):  
Michalis Hamilos ◽  
Stylianos Petousis ◽  
Ioanna Xanthopoulou ◽  
John Goudevenos ◽  
John Kanakakis ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Acute Coronary Syndrome ◽  
Coronary Intervention ◽  
Diabetic Patients ◽  
Antiplatelet Treatment ◽  
Coronary Syndrome ◽  
Percutaneous Coronary

scholarly journals Clopidogrel or ticagrelor alongside dabigatran in acute coronary syndrome and indication for NOAC: a study rationale

2021 ◽  
Author(s):  
Jasper Luijkx ◽  
Patty Winkler ◽  
Arnoud van 't Hof
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Acute Coronary Syndrome ◽  
Controlled Trial ◽  
Oral Anticoagulants ◽  
Academic Research ◽  
Coronary Intervention ◽  
Open Label ◽  
P2y12 Inhibitors ◽  
Coronary Syndrome ◽  
Percutaneous Coronary

The combination of oral anticoagulants with platelet inhibitors has been widely investigated in patients with coronary stenting and concomitant atrial fibrillation. In these patients, default therapy after percutaneous coronary intervention in acute coronary syndrome is clopidogrel plus non–vitamin K antagonist oral anticoagulant, omitting aspirin. However, in view of the high thromboembolic risk associated with acute coronary syndrome and the number of poor metabolizers for clopidogrel, investigation of alternative P2Y12-inhibitors is mandatory. This prospective, multicenter, open-label, registry-based, randomized, controlled trial aims to show the non-inferiority of dabigatran plus ticagrelor versus dabigatran plus clopidogrel in patients on chronic anticoagulants who undergo percutaneous coronary intervention in acute coronary syndrome. The primary end point is major bleeding as defined by the Bleeding Academic Research Consortium bleeding definition. Trial registration number: NL75644.096.21

Sign in / Sign up

Export Citation Format

Share Document